Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657587 | 0.86 | MAPK10 (0.33) | PIK3CA | |
| SCHEMBL2655858 | 0.84 | PIK3CA (0.38) | PIK3CAJAK2 | |
| SCHEMBL2661039 | 0.83 | BACE1 (0.33) | HRH4 | |
| SCHEMBL2661204 | 0.82 | LCK (0.32) | — | |
| SCHEMBL2661564 | 0.82 | DPP4 (0.33) | JAK2 | |
| SCHEMBL2661474 | 0.82 | HRH4 (0.32) | HRH4EGLN2 | |
| SCHEMBL2660899 | 0.81 | PDE4A (0.41) | PIK3CAPDE9APDE4AHRH4SYK | |
| SCHEMBL2657512 | 0.81 | CNR2 (0.46) | PDE9A | |
| SCHEMBL2656158 | 0.81 | ADORA2A (0.32) | HRH4JAK2 | |
| SCHEMBL2656102 | 0.80 | GABRG2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | claimed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | PIK3CA 3396/4885PDE9A 1059/4885PDE4A 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.